Cannara Biotech Inc. (TSX:LOVE)
Canada · Delayed Price · Currency is CAD | Market Cap | 169.91M +29.0% |
| Revenue (ttm) | 113.01M +20.1% |
| Net Income | 10.16M -24.2% |
| EPS | 0.11 -21.7% |
| Shares Out | 98.78M |
| PE Ratio | 15.82 |
| Forward PE | 11.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 45,841 |
| Average Volume | 58,131 |
| Open | 1.710 |
| Previous Close | 1.720 |
| Day's Range | 1.700 - 1.750 |
| 52-Week Range | 1.080 - 2.070 |
| Beta | 0.38 |
| RSI | 41.35 |
| Earnings Date | Jul 20, 2026 |
About Cannara Biotech
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. In addition, it engages in the real estate operations. Cannara Biotech Inc. was incorporated in 2017 and is headquartered in Saint-Laurent, Canada. [Read more]
Full Company ProfileFinancial Performance
In fiscal year 2025, Cannara Biotech's revenue was 107.20 million, an increase of 31.14% compared to the previous year's 81.75 million. Earnings were 13.08 million, an increase of 103.09%.
Financial StatementsNews
Cannara Biotech Earnings Call Transcript: Q2 2026
Q2 saw revenue rise to CAD 27.2M with strong margins and market share gains, especially in Quebec, despite industry seasonality. Strategic investments, new product launches, and capacity expansion position the business for continued growth and international opportunities.
Cannara Reports Q2 Fiscal 2026 Results with Continued Profitability, Strong Operating Cash Flow and #1 Retail Market Share in Québec
Cannara Releases Q2 FY26 Results: $27.2M revenue, 43% GM, $6.0M Adj. EBITDA, OCF $2.9M; 4.4% national share, #1 Québec; Valleyfield expansion progressing.
Video - CEO Clips: Cannara Biotech Graduates to Toronto Stock Exchange
Vancouver, British Columbia--(Newsfile Corp. - March 19, 2026) - Cannara Biotech Inc. (TSX: LOVE) (OTCQX: LOVFF) (FSE: 8CB0) is a vertically integrated producer of affordable premium-grade cannabis an...
Cannara Biotech Inc. (LOVE) Opens the Market
Toronto, Ontario--(Newsfile Corp. - March 17, 2026) - Donald Olds, Lead Director and Chairman of the Audit and Governance Committee, Cannara Biotech Inc. ("Cannara" or the "Company") (TSX: LOVE), toge...
Cannara Biotech graduates to TSX
Cannara Biotech (LOVFF) received final approval to graduate from the TSX Venture Exchange to the Toronto Stock Exchange. In connection with the Uplisting, the Company’s common shares will commence tra...
Cannara Biotech initiated with a Buy at TD Securities
TD Securities analyst Derek Lessard initiated coverage of Cannara Biotech (LOVFF) with a Buy rating and C$3.25 price target calling it the firm’s “top pure-play recreational Canadian LP pick.” Cannara
Cannara Biotech Transcript: Status update
Disciplined growth, strong brand portfolio, and operational efficiency have driven rising market share and profitability, with a clear, capital-efficient expansion plan and robust financials. Strategic capital raises and TSX uplisting aim to enhance liquidity and investor access.
Cannara Biotech prices 3M shares at C$2.10 in private placement
Cannara Biotech (LOVFF) completed a strategic, non-brokered private placement with Phoenician Capital. Pursuant to the terms of a subscription agreement, Phoenician has agreed to subscribe for 3,000,0...
Cannara Biotech announces conditional approval to list on TSX
Cannara Biotech (LOVFF) has received conditional approval to uplist its common shares to the Toronto Stock Exchange from the TSX Venture Exchange.
Cannara Biotech reports Q1 EPS C$0.01 vs. C$0.03 last year
Reports Q1 revenue C$30.1M vs. $25.1M last year. “Our continued market share expansion in Q1 2026 reflects the strength of our brands and our disciplined approach to growth,” said Zohar
Cannara Biotech Earnings Call Transcript: Q1 2026
Record Q1 2026 results with 20% net revenue growth year-over-year, 45% gross margin, and strong cash flow. Market share leadership in Quebec and national gains driven by premium product launches and disciplined expansion.
Cannara Biotech achieves OTCQX qualification
Cannara Biotech (LOVFF) has qualified to have its common shares quoted for trading on the OTCQX Best Market. Cannara’s common shares were previously quoted on the OTCQB Venture Market. Cannara’s
OTC Markets welcomes Cannara Biotech to OTCQX
OTC Markets Group announced Cannara Biotech (LOVFF) has qualified to trade on the OTCQX Best Market. Cannara Biotech Inc. upgraded to OTCQX from the OTCQB Venture Market. Published first on
Cannara Biotech provides update on Quebec vape category launch
Cannara Biotech (LOVFF) announced preliminary success in the Quebec provincial vape cartridge category launch. Estimated retail sales data indicates multiple leadership positions across the nascent ca...
Cannara Achieves #1 Market Share Position in Québec as of December 2025 and Provides Update on Québec Vape Category Launch
MONTREAL, Québec, Jan. 02, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-g...
Cannara Biotech reports FY25 EPS C$0.14 vs. C$0.07 last year
Reports FY25 revenue C$107.3M vs. C$82.2M last year. “Fiscal 2025 represents the strongest annual performance in Cannara Biotech’s (LOVFF) history and reflects our ability to execute on the significan...
Cannara Biotech Earnings Call Transcript: Q4 2025
Fiscal 2025 set new records in revenue, profit, and cash flow, driven by expanded capacity and operational efficiency. Market share surged across key provinces, with leadership in several product categories. Continued growth and margin improvement are expected as further expansion comes online.
Cannara Biotech Transcript: Planet MicroCap Showcase: TORONTO 2025
Operating two major Quebec facilities, the company is profitable, cash flow positive, and rapidly scaling production. With strong brand loyalty in Quebec, a focus on genetics, and new vape products launching, it targets further growth while maintaining disciplined inventory and expansion strategies.
Cannara Biotech announces DTC eligibility to facilitate U.S. investor access
Cannara Biotech (LOVFF) announced that the common shares of the Company are now eligible for electronic clearing and settlement in the United States through The Depository Trust Company. DTC eligibili...
Cannara Announces DTC Eligibility to Facilitate U.S. Investor Access and Strengthens Balance Sheet through completion of Debt-to-Equity Conversion
Cannara secures DTC eligibility to expand U.S. investor access and completes $6.2M debt-to-equity conversion, strengthening liquidity and balance sheet.
Cannara Biotech announces proposed setllement of convertible debenture
Cannara Biotech (LOVFF) announced its intention to settle an aggregate of approximately $6.2M of indebtedness, consisting of $4.7M in principal and approximately $1.5M in accrued interest, under its c...
Cannara Announces Proposed Settlement of Convertible Debenture via Share Issuance
MONTREAL, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade can...
Cannara Biotech Transcript: Q3 Investor Summit Group Virtual Conference 2025
A leading vertically integrated cannabis producer in Quebec reported record financial results, strong market share growth, and operational efficiencies. Strategic facility investments and proprietary genetics drive scalable expansion, with a focus on premium products and disciplined capital management.
Cannara Announces Grant of Options and RSUs
MONTREAL, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade ca...
Cannara Biotech announces amendment, upsize of BMO credit facility
Cannara Biotech (LOVFF) announced amendments to its existing credit facility with Bank of Montreal acting as administrative agent, lead arranger, syndication agent and sole bookrunner, including a $10...